TY - JOUR
T1 - Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma
AU - Dickinson, Michael
AU - Martinez-Lopez, Joaquin
AU - Jousseaume, Etienne
AU - Yang, Hongbo
AU - Chai, Xinglei
AU - Xiang, Cheryl
AU - Wang, Travis
AU - Zhang, Jie
AU - Ramos, Roberto
AU - Schuster, Stephen J.
AU - Fowler, Nathan
N1 - Publisher Copyright:
© 2024 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - Regulatory approvals of tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) have established the feasibility of chimeric antigen receptor T-cell therapies for the treatment of adults with relapsed or refractory follicular lymphoma (r/r FL). This study used individual patient data from ELARA (tisa-cel) and aggregate published patient data from ZUMA-5 (axi-cel) to compare efficacy and safety outcomes in r/r FL using matching-adjusted indirect comparison methods. After adjustment for baseline differences in the trial populations, the results suggested that tisa-cel (n = 52), compared with axi-cel (n = 86), had similar effects on overall response rate (91.2% vs. 94.2%; p = .58), complete response rate (74.0% vs. 79.1%; p = .60), progression-free survival (HR [95% CI]: 0.8 [0.4, 1.9]; p = .67), and overall survival (HR [95% CI]: 0.5 [0.2, 1.5]; p = .21). Tisa-cel (n = 53) was associated with better safety outcomes than axi-cel (n = 124), reflected by lower rates of any grade and grade ≥3 cytokine release syndrome and neurological events.
AB - Regulatory approvals of tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) have established the feasibility of chimeric antigen receptor T-cell therapies for the treatment of adults with relapsed or refractory follicular lymphoma (r/r FL). This study used individual patient data from ELARA (tisa-cel) and aggregate published patient data from ZUMA-5 (axi-cel) to compare efficacy and safety outcomes in r/r FL using matching-adjusted indirect comparison methods. After adjustment for baseline differences in the trial populations, the results suggested that tisa-cel (n = 52), compared with axi-cel (n = 86), had similar effects on overall response rate (91.2% vs. 94.2%; p = .58), complete response rate (74.0% vs. 79.1%; p = .60), progression-free survival (HR [95% CI]: 0.8 [0.4, 1.9]; p = .67), and overall survival (HR [95% CI]: 0.5 [0.2, 1.5]; p = .21). Tisa-cel (n = 53) was associated with better safety outcomes than axi-cel (n = 124), reflected by lower rates of any grade and grade ≥3 cytokine release syndrome and neurological events.
KW - Relapsed/refractory follicular lymphoma
KW - axicabtagene ciloleucel
KW - matching-adjusted indirect comparison
KW - tisagenlecleucel
UR - http://www.scopus.com/inward/record.url?scp=85181478547&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85181478547&partnerID=8YFLogxK
U2 - 10.1080/10428194.2023.2289854
DO - 10.1080/10428194.2023.2289854
M3 - Article
C2 - 38179688
AN - SCOPUS:85181478547
SN - 1042-8194
VL - 65
SP - 323
EP - 332
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 3
ER -